Chemomab investor reports 1.2% ADS stake

Chemomab Therapeutics Ltd. investor Erik Otto filed an amended Schedule 13G reporting his beneficial ownership of the company’s American Depository Shares (ADSs).

Rhea-AI Filing Summary

Chemomab Therapeutics Ltd. investor Erik Otto filed an amended Schedule 13G reporting his beneficial ownership of the company’s American Depository Shares (ADSs). He reports beneficial ownership of 90,000 ADSs, each ADS representing twenty ordinary shares with no par value.

Based on 7,200,377 ADSs outstanding as of May 14, 2026, this position represents 1.2% of the class. Otto reports sole voting power and sole dispositive power over all 90,000 ADSs, with no shared voting or dispositive power. The holding is explicitly disclosed as ownership of 5 percent or less of the class.

Key Figures

ADSs beneficially owned: 90,000 ADSs Ownership percentage: 1.2% ADSs outstanding: 7,200,377 ADSs +2 more

5 metrics

ADSs beneficially owned 90,000 ADSs Amount beneficially owned by Erik Otto

Ownership percentage 1.2% Percent of Chemomab ADS class owned by Erik Otto

ADSs outstanding 7,200,377 ADSs ADSs outstanding as of May 14, 2026, as provided by issuer

Sole voting power 90,000 ADSs Shares over which Erik Otto has sole voting power

Sole dispositive power 90,000 ADSs Shares over which Erik Otto has sole dispositive power

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, American Depository Shares, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: 90000"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"Sole Voting Power 90,000.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"Sole Dispositive Power 90,000.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

American Depository Shares financial

"Title of class of securities: American Depository Shares"

American depository shares are U.S.-listed securities that stand in for a foreign company’s ordinary shares, held by a U.S. bank which issues the ADS so investors can trade the foreign stock in U.S. dollars and on U.S. exchanges. Think of them like a locally wrapped version of a foreign product—easier to buy and sell at home—but they still carry risks from currency differences, foreign rules and potential limits on voting rights, so they affect access, liquidity and investment risk.

percent of class financial

"Percent of class: 1.2 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Chemomab Therapeutics (CMMB) does Erik Otto report owning in this 13G/A?

Erik Otto reports owning 1.2% of Chemomab Therapeutics’ ADSs. This percentage is based on 7,200,377 ADSs outstanding as of May 14, 2026, as provided by the issuer.

How many Chemomab Therapeutics (CMMB) ADSs does Erik Otto beneficially own?

Erik Otto reports beneficial ownership of 90,000 American Depository Shares (ADSs) of Chemomab Therapeutics. He has sole voting and sole dispositive power over all 90,000 ADSs, with no shared power reported.

What is the ADS share count used to calculate Erik Otto’s 1.2% stake in CMMB?

The 1.2% ownership is calculated using 7,200,377 ADSs outstanding as of May 14, 2026. This outstanding share count was provided by the issuer, Chemomab Therapeutics Ltd.

Does Erik Otto share voting or dispositive power over his Chemomab (CMMB) ADS holdings?

No. Erik Otto reports sole voting power over 90,000 ADSs and sole dispositive power over 90,000 ADSs. He reports no shared voting power and no shared dispositive power for these securities.

What class of Chemomab Therapeutics (CMMB) securities is covered in Erik Otto’s Schedule 13G/A?

The filing covers American Depository Shares (ADSs) of Chemomab Therapeutics Ltd., each ADS representing twenty ordinary shares with no par value, identified by CUSIP 36322Q107.

Does Erik Otto’s Chemomab (CMMB) position exceed 5% ownership of the class?

No. Erik Otto’s position is explicitly reported as 1.2% of the class, and the filing confirms Ownership of 5 percent or less of a class, keeping him below the 5% threshold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 11:58 AM Accepted by SEC EDGAR 08/10/2026 - 11:58 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Chemomab Therapeutics Ltd.

(Name of Issuer)

American Depository Shares, each of which represent twenty ordinary shares, no par value

(Title of Class of Securities)

36322Q107

(CUSIP Number)

08/10/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 36322Q107

1

Names of Reporting Persons

Otto Erik

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CANADA (FEDERAL LEVEL)

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 90,000.00
6	Shared Voting Power
7	Sole Dispositive Power 90,000.00
8	Shared Dispositive Power

9

Aggregate Amount Beneficially Owned by Each Reporting Person

90,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.2 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: *Percent of class represented by Row (11) based on 7,200,377 ADSs outstanding as of May 14th, 2026 (As provided by the Issuer)

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Chemomab Therapeutics Ltd.
(b)	Address of issuer's principal executive offices: KIRYAT ATIDIM, BUILDING 7, TEL AVIV, ISRAEL, 6158101
Item 2.
(a)	Name of person filing: Erik Otto
(b)	Address or principal business office or, if none, residence: 144 West Oakview Place, San Antonio, TX 78209
(c)	Citizenship: Canada
(d)	Title of class of securities: American Depository Shares, each of which represent twenty ordinary shares, no par value
(e)	CUSIP No.: 36322Q107
Item 4.	Ownership
(a)	Amount beneficially owned: 90000
(b)	Percent of class: 1.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 90000
	(ii) Shared power to vote or to direct the vote:
	(iii) Sole power to dispose or to direct the disposition of: 90000
	(iv) Shared power to dispose or to direct the disposition of:
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Otto Erik

Signature:	Erik Otto
Name/Title:	Individual
Date:	08/10/2026